IPO Recap: Sports betting and data firm Sportradar started trading

At the close on the last trading day, the Dow Jones Industrial Average lost0.84%, while the S&P 500 index fell0.57%, and the NASDAQ Composite index lost0.45%.

The Post Labor Day IPO storm is coming this week and several large IPOs will be listed.

On the last trading day, there was one traditional IPO filed and one new stock officially listed for trading.

MiNK Therapeutics, founded in 2017, is a Phase 1 biotech developing allogenic T cell therapies for cancer and immune-mediated diseases.

MiNK Therapeutics' lead program, AGENT-797, is an allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapy targeting cancer and other immune-mediated diseases. The company claims that iNKT cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host disease. AGENT-797 is currently conducting a Phase 1 trial in multiple myeloma patients that is expected to report top-line data in the fourth quarter of 2021.

Sportradar offers robust and fully integrated sports data and technology platforms. It serves as a critical data infrastructure and content layer to the sports betting and media industries. On top of that infrastructure layer, it has built advanced and comprehensive software offerings.

Sportradar leads on the breadth of events coverage for sports data and odds. It collects over 1.2 billion live data points per year from over 600,000 events in 37 sports.

Related:

Bentley delivers solutions for the entire lifecycle of the infrastructure asset, tailored to the needs of the various professions – the engineers, architects, geospatial professionals, planners, contractors, fabricators, IT managers, operators and maintenance engineers – who will work on and work with that asset over its lifetime.

As of September 15th, it has a market cap of $19.48 billion, with the listed to date gain of 214.32%.